Stockscreener 앱 받기
0.3517
5.02%
0.0168
시간 외 거래:
.36
0.0083
+2.36%
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
Medicus Pharma Ltd. (MDCX) has officially submitted an application to the United States Food and Drug Administration (FDA) seeking Rare Pediatric Disease Designation for its investigational product Skinject® for the indication of Gorlin syndrome. - Bitget
Medicus advances Teverelix development with EU Phase 2b trial submission in Prostate Cancer - Proactive financial news
Medicus advances Teverelix and SkinJect programs with key regulatory filings - Proactive financial news
Small cap wrap: Medicus Pharma, First Phosphate, Standard Uranium... - Proactive financial news
Medicus Dips on FDA Nod - Baystreet.ca
Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome - Proactive financial news
Medicus Pharma seeks rare pediatric disease status for patch - Investing.com
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome - The Manila Times
Medicus Pharma files for RPDD for SkinJect in gorlin syndrome - grafa.com
This $9 SpaceX Stock Has Crazy Potential Geena Davis (jBXkEb6qgn) - Mshale
MDCX Stock Price, Quote & Chart - ChartMill
Medicus Pharma on Bloomberg World - South Bend Tribune
MDCX News | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - South Bend Tribune
Medicus Pharma (NASDAQ:MDCX) Share Price | RNS News, Quotes, & Charts | MDCX | - Proactive Investors
Small cap wrap: Fineqia, Phunware, Medicus Pharma... - Proactive financial news
Medicus Pharma Submits Ind Application for PRECISION-E2 Phase 2A Study of Teverelix in Endometriosis in United Arab Emirates - marketscreener.com
Medicus Pharma files IND for genomics-enabled endometriosis trial in UAE - Yahoo Finance
Medicus Pharma submits IND application for endometriosis trial By Investing.com - Investing.com Australia
Medicus Pharma submits IND application for endometriosis trial - Investing.com
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program - The Manila Times
Medicus Pharma Ltd. Submits IND Application for Innovative PRECISION-E2 Phase 2a Clinical Trial in Endometriosis - Quiver Quantitative
UAE study uses Emirati genome data to tailor endometriosis treatment - Stock Titan
Medicus Pharma submits endometriosis IND in Abu Dhabi - grafa.com
MDCX Q1 2026 Earnings: EPS Miss as Losses Deepen, Stock DeclinesRevenue Growth Outlook - newsline.com
ICYMI: Medicus Advances SkinJect Into Registrational Study for Rare Disorder - MyChesCo
Small cap wrap: Grey Matters Health, Medicus Pharma, ReconAfrica, EnWave... - Proactive financial news
Medicus submits EU filing for Teverelix prostate cancer study - Investing.com UK
Medicus Pharma submits EU clinical trial modification for prostate cancer drug Teverelix - Yahoo Finance
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission - The Manila Times
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High ... - Caledonian Record
Medicus Pharma Advances Teverelix® Program Towards - GlobeNewswire
Medicus Pharma advances SkinJect for Gorlin syndrome – ICYMI - Proactive financial news
Medicus Pharma reports dose response data from skin cancer study - Investing.com
This $9 SpaceX Stock Has Crazy Potential (v8s49pRqnF) - Fathom Journal
Medicus Pharma advances SkinJect toward registrational trial for rare Gorlin Syndrome - Proactive financial news
Medicus Pharma Ltd. Files Form 8-K: Company Information, NASDAQ Listing, and Key Details (June 2026) - Minichart
Medicus Pharma Shareholders Approve Auditor, Board and Consolidation - TipRanks
Medicus Pharma (MDCX) registers 3.25M shares; warrants exercisable at $4.64 - Stock Titan
Shareholders at Medicus Pharma (NASDAQ: MDCX) approve reverse split authority - Stock Titan
Medicus Pharma (MDCX) COO awarded 200,000 options at $0.36 exercise price - Stock Titan
Medicus Pharma (MDCX) director receives 50,000 stock options at $0.36 strike - Stock Titan
Medicus Pharma (MDCX) awards CMO 250,000 options at $0.36 strike - Stock Titan
Director at Medicus Pharma (MDCX) receives grant of 50,000 stock options - Stock Titan
Director Patrick Mahaffy receives 50,000 Medicus Pharma (MDCX) stock options at $0.36 - Stock Titan
Maxim Group Maintains Medicus Pharma(MDCX.US) With Buy Rating, Maintains Target Price $2 - Moomoo
Medicus Pharma (MDCX) director Larry Kaiser awarded 50,000 options at $0.36 - Stock Titan
Director Barry Fishman receives 50,000 stock options at Medicus Pharma (MDCX) - Stock Titan
Medicus Pharma (MDCX) grants director 50,000 stock options at $0.36 - Stock Titan
Medicus Pharma (MDCX) Chief Scientific Officer awarded 25,000 options at $0.36 - Stock Titan
Medicus Pharma (MDCX) President and CFO awarded 250,000 stock options at $0.36 - Stock Titan
Medicus Pharma (MDCX) CEO awarded 500,000 options at $0.36 exercise price - Stock Titan
0.46%
0.23%
자본화:
|
볼륨(24시간):